NCT05363397View on ClinicalTrials.gov

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

PHASE2SuspendedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 27, 2023

Primary Completion Date

February 1, 2026

Study Completion Date

May 1, 2026

Conditions
Acute Ischemic Stroke
Interventions
DRUG

TBO-309

TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

Trial Locations (6)

2031

Prince of Wales Hospital, Randwick

2050

Timothy Ang, Camperdown

2170

Liverpool Hospital, Liverpool

2305

John Hunter Hospital, New Lambton Heights

3050

Royal Melbourne Hospital, Parkville

5000

Royal Adelaide Hospital, Adelaide

Sponsors
All Listed Sponsors
collaborator

Neuroscience Trials Australia

OTHER

lead

The Florey Institute of Neuroscience and Mental Health

OTHER

NCT05363397 - Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke | Biotech Hunter | Biotech Hunter